Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, Ronald Hoffman, John Mascarenhas et al.|Blood|2019Cited by 175
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S. Wang, Amir T. Fathi, Ghayas C. Issa et al.|The Lancet Oncology|2024Cited by 106
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Vikas Gupta, Marina Kremyanskaya et al.|Journal of Clinical Oncology|2023Cited by 89
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phaseJohn Mascarenhas, Ronald Hoffman, Raajit K. Rampal et al.|Blood Advances|2020Cited by 74
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid LeukemiaHarry P. Erba, Eunice S. Wang, Amir T. Fathi et al.|Blood|2022Cited by 71